BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38541077)

  • 21. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
    Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
    Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
    Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fast Diagnostics of BRAF Mutations in Biopsies from Malignant Melanoma.
    Huber F; Lang HP; Glatz K; Rimoldi D; Meyer E; Gerber C
    Nano Lett; 2016 Sep; 16(9):5373-7. PubMed ID: 27490749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur.
    Kang X; Zeng Y; Liang J; Li J; Ren D; Chai L; Sun Z; Yu S; Wu X; Han W; Wang W
    Medicine (Baltimore); 2018 Jan; 97(1):e9509. PubMed ID: 29505523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
    Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
    J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis.
    Xing H; Song Y; Zhang Z; Koch PD
    J Mol Neurosci; 2021 Sep; 71(9):1815-1824. PubMed ID: 33791912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults.
    Estrozi B; Machado J; Rodriguez R; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):57-64. PubMed ID: 24471189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
    Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
    PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
    Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
    Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
    J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
    Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
    Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.